<i>Staphylococcus aureus</i> and Vancomycin: The Sequel
Authors: Adolf W. Karchmer
Journal: Annals of Internal Medicine (1991)

Editorials1 November 1991Staphylococcus aureus and Vancomycin: The SequelAdolf W. Karchmer, MDAdolf W. Karchmer, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-115-9-739 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptCurrently, among the many bacterial infections,Staphylococcus aureusinfection is often considered to be troublesome but manageable with available antimicrobials. However, when viewed from a broader perspective, such complacency might be challenged.Staphylococcus aureushas demonstrated remarkable persistence and genetic versatility, which have allowed it to keep pace with modern medicine and antimicrobial development. During the early antimicrobial era,S. aureusbacteremia, with or without concurrent endocarditis, was a dreaded infection and was associated with a mortality rate of 80%. Initially, the introduction of penicillin reduced the death rate to 30% (1). However, the emergence of penicillinase-producingS. aureusas...References1. Spink W. Staphylococcal infections and problem of antibiotic resistant staphylococci. Arch Intern Med. 1954;94:167-96. CrossrefGoogle Scholar2. KirbyPerryBauer WDA. Treatment of staphylococcal septicemia with vancomycin: report of thirty-three cases. N Engl J Med. 1960;262:49-55. CrossrefMedlineGoogle Scholar3. LevineFrommReddy DBB. Delayed response to vancomycin or vancomycin plus rifampin therapy among patients with methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 1991;115:674-80. LinkGoogle Scholar4. SmallChambers PH. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990;34:1227-31. CrossrefMedlineGoogle Scholar5. BayerBlomquistBelloChiuWardGinzton AIECJL. Tricuspid valve endocarditis due to Staphylococcus aureus: correlation of two-dimensional echocardiography with clinical outcome. Chest 1988;93:247-53. CrossrefMedlineGoogle Scholar6. LevineCraneZervos DLM. Bacteremia in narcotic addicts at the Detroit Medical Center. II. Infectious Endocarditis: a prospective comparative study. Rev Infect Dis. 1986;8:374-96. CrossrefMedlineGoogle Scholar7. KorzeniowskiSande OM. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med. 1982;97:496-503. LinkGoogle Scholar8. EngBishburgSmithScadutto RESP. Staphylococcus aureus bacteremia during therapy. J Infect Dis. 1987;155:1331-5. CrossrefMedlineGoogle Scholar9. EhniReller WB. Short-course therapy for catheter-associated Staphylococcus aureus bacteremia. Arch Intern Med. 1989;149:533-6. CrossrefMedlineGoogle Scholar10. SorrellPackhamShankerFoldesMunro TDSMR. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982;97:344-50. LinkGoogle Scholar11. CantoniGlauserBille LMJ. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother. 1990;34:2348-53. CrossrefMedlineGoogle Scholar12. CantoniWengerGlauserBille LAMJ. Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats. J Infect Dis. 1989;159:989-93. CrossrefMedlineGoogle Scholar13. Boyce J. Methicillin-resistant Staphylococcus aureus: detection, epidemiology, and control measures. Infect Dis Clin North Am. 1989;3:901-13. CrossrefMedlineGoogle Scholar14. StorchRadcliffMeyerHinrichs GJPJ. Methicillin-resistant Staphylococcus aureus in a nursing home. Infect Control. 1987;8:24-9. CrossrefMedlineGoogle Scholar15. SaravolatzPohlodArking LDL. Community-acquired methicillin-resistant Staphylococcus aureus infections: A new source for nosocomial outbreaks. Ann Intern Med. 1982;97:325-9. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New England Deaconess Hospital and Harvard Medical School Boston, Massachusetts PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByThe negative impact of antibiotic resistanceRelationship of teicoplanin MICs to treatment failure in teicoplanin-treated patients with methicillin-resistant Staphylococcus aureus pneumoniaTrends in Incidence and Susceptibility among Methicillin-Resistant Staphylococcus aureus Isolated from Intranasal Cultures Associated with RhinosinusitisGenotypically Different Clones of Staphylococcus aureus Are Diverse in the Antimicrobial Susceptibility Patterns and Biofilm FormationsPrevalence and Outcomes of Antimicrobial Treatment for Staphylococcus aureus Bacteremia in Outpatients with ESRDPenicillinallergie: Mythos und FaktenEfficacy of Vancomycin against Staphylococcus aureus according to Inoculum Size in a Neutropenic Mouse Infection ModelInfective Endocarditis and Its Mimics inCriticalCareComparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in TaiwanGlycopeptide PharmacodynamicsSeptic ShockCase-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysisEffects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemiaTreatment of intra-abdominal and skin and soft tissue infections: The role of the glycylcyclinesAdaptation of Methicillin-Resistant Staphylococcus aureus in the Face of Vancomycin TherapyShort-Course Gentamicin in Combination with Daptomycin or Vancomycin against Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial VegetationsIn vivo synergy of daptomycin plus a penicillin agent for MRSA?Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy SubjectsStaphylococcal Skin Infections in ChildrenImpact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic ModelMethicillin-resistant Staphylococcus aureus infections in ICU patientsIs the Burden of Staphylococcus aureus Among Patients With Surgical-Site Infections Growing?Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus BacteremiaTratamento e prevenção das infecções e da colonização por Staphylococcus aureusInfection of Transjugular Intrahepatic Portosystemic Shunt DevicesVancomycin for Staphylococcus aureus therapy of respiratory tract infections: the end of an era?Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical TrialEconomic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical modelAktuelle Therapie der Infektiösen EndokarditisANTISTAPHYLOCOCCAL (MSSA, MRSA, MSSE, MRSE) ANTIBIOTICSScreening for methicillin-resistant Staphylococcus aureus in the endemic hospital: what have we learned?Vancomycin resistance in Staphylococcus aureus: a new challenge for infection control and antibiotic prescribingIndications for Vancomycin in Dialysis PatientsVancomycin prescribing practices in hospitalized chronic hemodialysis patientsInfective Endocarditis: a Diagnostic and Therapeutic Challenge for the New MillenniumShould Once-Daily Vancomycin in the Treatment of Infective Endocarditis Be Reassessed?Analysis of Vancomycin Population Susceptibility Profiles, Killing Activity, and Postantibiotic Effect against Vancomycin-Intermediate Staphylococcus aureusVancomycin-Induced Acute Interstitial NephritisStaphylococcus aureus InfectionsClinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistanceANTIMICROBIAL RESISTANCE IN STAPHYLOCOCCIAntibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices?Drug-resistant staphylococcal infectionsInappropriate Vancomycin Prescribing Based on Criteria from the Centers for Disease Control and PreventionRecurrent Methicillin-Resistant Staphylococcus Aureus Osteomyelitis: Combination Antibiotic Therapy with Evaluation by Serum Bactericidal TitersAntimicrobial Resistance in StaphylococciPotential of clindamycin in addition to vancomycin for the treatment of oxacillin-resistant Staphylococcus aureus septicemia persisting under vancomycin therapyVancomycinTeicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureusProspective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditisBeta-lactams versus glycopeptides in treatment of subcutaneous abscesses infected with Staphylococcus aureusMethicillin-resistant Staphylococcus Aureus InfectionImpact of Antimicrobial Resistance on Therapy of Bacterial Pneumonia in Children 1 November 1991Volume 115, Issue 9Page: 739-741KeywordsAntimicrobialsBacteremiaDeath ratesEndocarditisGeneticsPenicillinStaphylococcal infectionStaphylococcus aureusVancomycin Issue Published: 1 November 1991 PDF DownloadLoading ...